\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours nor response.	0.5										

Arduini Peter J		on*	2. Issuer Name and Ticker or Trading Symbol INTEGRA LIFESCIENCES HOLDINGS	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
			CORP [IART]	X	Director	10% Owner			
(I, +)		(8.4:-1-11-)			Officer (give title below)	Other (specify below)			
(Last) (First) (Middle) 1100 CAMPUS ROAD		(Midale)	3. Date of Earliest Transaction (Month/Day/Year) 02/13/2020		CEO				
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indi [.] Line)	vidual or Joint/Group Filin	g (Check Applicable			
PRINCETON	NJ	08540		X	Form filed by One Rep	orting Person			
(City)	(State)	(Zip)			Form filed by More tha Person	n One Reporting			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	3. Transa Code (5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial
	((Month/Day/Year)		v	Amount	(A) or (D)	Price	Owned Following Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	02/13/2020		A		27,730 ⁽¹⁾	A	\$0.00	210,747	D	
Common Stock	02/13/2020		A		15,512 ⁽²⁾	A	\$0.00	226,259	D	
Common Stock	02/13/2020		Α		16,316 ⁽³⁾	A	\$0.00	242,575	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nur of Deriv Secur Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	Expiration Date (Month/Day/Year) ed		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019, at least 9% and up to a maximum of 33% cumulative increase in annual revenue over the 2016 fiscal year, under the March 13, 2017 Performance Stock Award. Accordingly, 34% of the shares will vest on March 13, 2020 at 150% of target, the third anniversary of the grant date. 2. On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2018 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the second anniversary of the grant date. 3. On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2019 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the second anniversary of the grant date. 3. On February 13, 2020, the Compensation Committee certified that the Company achieved its performance goal for fiscal year 2019 under the March 13, 2019 performance stock award at or above the threshold level based on annual organic revenue growth over the prior fiscal year. Accordingly, 33% of the shares will vest on March 13, 2020 at 97% of target, the first anniversary of the grant date. **Remarks:**

/s/ Eric Schwartz; Attorney-in-02/18/2020

04/10/2

** Signature of Reporting Person Date

Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.